Program Overview and Goals

The PROTEA team engages in a variety of research efforts at UW and beyond with collaborations around the country. The overarching goals for our research program comprise the enhancement of treatment and prevention for substance use disorders, substance misuse, and related conditions. As such, we engage in a program of research that spans efforts from clinical efficacy trials through translational investigations in health services research and implementation science.

Community-Engaged and Health Services Research

Funding Source: NIH-NIDA

Principal Investigator: John Curtain (Psychology); Randall Brown Co-I

Description: The broad goals of this project are to develop and deliver a highly contextualized, lapse risk prediction models for forecasting day-by-day probability of opioid and other drug use lapse among people pursuing drug abstinence. This lapse risk prediction model will be delivered within the Addiction-Comprehensive Health Enhancement Support System (A-CHESS) mobile app, which has been established by RCT as a state-of-the-art mHealth system for providing continuing care services for alcohol and substance use disorders.

Funding Source: NIH-NIDA

Principal Investigator: Andrew Quanbeck (DFMCH); Randall Brown Co-I

Description: The research aims to identify which sequence and combination of implementation strategies works most effectively in promoting practice change in different primary care clinics. The research serves the long-term goal of learning how to optimize implementation strategies to promote evidence-based practice in primary care settings.

Funding Source: NIH-NIDA

Principal Investigator: Andrew Quanbeck (DFMCH); Randall Brown Co-I

Description: The research aims to identify which sequence and combination of implementation strategies works most effectively in promoting practice change in different primary care clinics. The research serves the long-term goal of learning how to optimize implementation strategies to promote evidence-based practice in primary care settings.

Funding Source: NIH-NIDA

Principal Investigator: Majid Afshar (Pulmonary & Critical Care Medicine); Randall Brown Co-I

Description: Documentation of substance use is common and occurs in 97% of provider admission notes, but their free text format renders them difficult to mine and analyze. Natural Language Processing (NLP) and machine learning are subfields of artificial intelligence (AI) that provide a solution to analyze text data in the EHR to identify substance misuse. Version of an NLP and machine learning tool, our opioid and alcohol misuse classifiers successfully used data from clinical notes collected in the first 24 hours of admission. We aim to train and test our substance misuse classifiers in a retrospective dataset of over 35,000 hospitalizations that have been manually screened with the universal screen, AUDIT, and DAST. The top performing classifier will then be tested prospectively to: (1) externally validate its screening performance in a hospital without established screening; and (2) test its effectiveness against usual care at a hospital with questionnaire-based substance misuse screening.

Funding Source: NIH-NIDA

Principal Investigator: Ryan Westergaard (Medicine); Randall Brown Co-I

Description: The project proposes a multi-phase, mixed-methods study that aims to implement and evaluate a novel community response model, which we have named the Community-Based, Client-Centered Prevention Home. Using the organizational infrastructure of a large, multi-site syringe service program serving a geographically dispersed population of people who inject drugs in rural communities across Northern Wisconsin, we will build locally responsive systems to facilitate uptake of evidence-based prevention services for high-risk clients.

Funding Source: NIH-NIDA 4R01DA030431-05

Principal Investigator: Todd Molfenter (Industrial & Systems Engineering); Randall Brown Co-I

Description: This trial will study the impact of Ohio counties (payers) and addiction treatment organizations working in partnership to remove systemic barriers to adoption of the evidence-based practice (EBP) buprenorphine, a medication for opioid dependence. While various implementation strategies have targeted clinicians and/or treatment provider organizations, we believe this to be among the first controlled studies to systematically study the impact payer and provider strategies have on the implementation and dissemination of an EBP.

Source: UWF – Wisconsin Partnership – MERC

Principal Investigator: Randall Brown; Christopher Nicholas Co-I; Bri Deyo Program Manager

Description: The long-term goal for this and future work is the dissemination of interventions effective in preventing opioid addiction and related complications, such as overdose, among victims of traumatic injury. The research specifically aims to engage the high-risk population of traumatic injury victims to develop an implementable set of opioid risk screening items.

Website: https://www.fammed.wisc.edu/stomp/

Funding Source: UW-Madison Department of Family Medicine and Community Health

Principal Investigator: Alyssa Tilhou

Description: The research aims to evaluate how people who use drugs (PWUD) modify drug use behavior in response to the use of fentanyl test strips (FTS). Utilizing interviews and surveys to gather information directly from PWUD, findings will yield insight into the safety of FTS as well as highlight behaviors perceived as feasible among PWUD to minimize the risk of harm. A secondary goal of this study is to provide knowledge about the penetration of fentanyl into the drug supply and provide information that can guide interventions to decrease the risk of overdose.

Psychedelic and MDMA Studies

Funding Source: Usona

Principal Investigator: Charles Raison (School of Human Ecology); Randall Brown Site PI; Christopher Nicholas Co-I; Bri Deyo Program Manager

Description: The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 8 post-dose.

Funding Source: UW Department of Family Medicine Small Grant

Principle Investigators: Christopher Nicholas and Bri Deyo

Description: Site initiated sub-study of the Usona Phase 2 trial examining the functional connectivity associated with therapeutic changes in cognitive flexibility following a single dose of psilocybin in adults with major depressive disorder.

Funding Source: Heffter Research Institute

Principal Investigator: Randall Brown

Description: Conduct a single arm feasibility study of 2 guided psilocybin sessions in addition to opioid agonist therapy (OAT) with buprenorphine/naloxone in a sample of 10 adult subjects with OUDs.

Source: Multi-Disciplinary Association for Psychedelic Studies (MAPS)

Principal Investigator: Rick Doblin (MAPS); Randall Brown & Christopher Nicholas Co-Site PI; Bri Deyo Program Manager

Description: This multi-site double-blind, placebo-controlled randomized Phase 3 study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy versus psychotherapy with placebo in participants diagnosed with at least severe posttraumatic stress disorder (PTSD).

Source: Revive Therapeutics

Principle Investigator: Christopher Nicholas

Description: Conduct a single arm feasibility study of two guided psilocybin sessions and pre-post dose functional neuroimaging in a sample of 12 adults with methamphetamine use disorder recruited from local HIV community care clinics.

PROTEA logo

Contact Us

PROTEA Team
Megan Ringo
Program Manager
Email: Contact »

Program Office

PROTEA
UW Dept. of Family Medicine
1100 Delaplaine Court
Alumni Hall
Madison, WI 53715